These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31907738)

  • 61. Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.
    Nakata K; Sakata K; Someya M; Miura K; Hayashi J; Hori M; Takagi M; Himi T; Kondo A; Hareyama M
    J Radiat Res; 2013 Jul; 54(4):679-83. PubMed ID: 23292146
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
    Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
    Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
    Yamaue H; Shimizu A; Hagiwara Y; Sho M; Yanagimoto H; Nakamori S; Ueno H; Ishii H; Kitano M; Sugimori K; Maguchi H; Ohkawa S; Imaoka H; Hashimoto D; Ueda K; Nebiki H; Nagakawa T; Isayama H; Yokota I; Ohashi Y; Shirasaka T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):813-823. PubMed ID: 28251282
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma.
    Furuse J; Okusaka T; Kaneko S; Kudo M; Nakachi K; Ueno H; Yamashita T; Ueshima K
    Cancer Sci; 2010 Dec; 101(12):2606-11. PubMed ID: 20946314
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
    Auvray M; Tougeron D; Auclin E; Moulin V; Artru P; Hautefeuille V; Hammel P; Lecomte T; Locher C; Sickersen G; Coriat R; Lecaille C; Vernerey D; Taieb J; Pernot S
    Clin Colorectal Cancer; 2020 Mar; 19(1):39-47.e5. PubMed ID: 31648924
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
    Chung KY; Saito K; Zergebel C; Hollywood E; Segal M; Saltz LB
    Oncology; 2011; 81(2):65-72. PubMed ID: 21968463
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
    Inokuchi M; Yamashita T; Yamada H; Kojima K; Ichikawa W; Nihei Z; Kawano T; Sugihara K
    Br J Cancer; 2006 Apr; 94(8):1130-5. PubMed ID: 16570038
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
    Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
    Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer.
    Koizumi W; Yamaguchi K; Hosaka H; Takinishi Y; Nakayama N; Hara T; Muro K; Baba H; Sasaki Y; Nishina T; Fuse N; Esaki T; Takagi M; Gotoh M; Sasaki T
    Br J Cancer; 2013 Oct; 109(8):2079-86. PubMed ID: 24045669
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
    Voss MH; Bhatt RS; Plimack ER; Rini BI; Alter RS; Beck JT; Wilson D; Zhang X; Mutyaba M; Glasser C; Attie KM; Sherman ML; Pandya SS; Atkins MB
    Clin Cancer Res; 2017 Jul; 23(14):3557-3565. PubMed ID: 28031424
    [No Abstract]   [Full Text] [Related]  

  • 77. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
    Ooka Y; Chiba T; Ogasawara S; Arai K; Suzuki E; Tawada A; Yamashita T; Kanai F; Kaneko S; Yokosuka O
    Invest New Drugs; 2014 Aug; 32(4):723-8. PubMed ID: 24599799
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
    Ajani JA; Faust J; Ikeda K; Yao JC; Anbe H; Carr KL; Houghton M; Urrea P
    J Clin Oncol; 2005 Oct; 23(28):6957-65. PubMed ID: 16145066
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer.
    Yamaguchi Y; Minami K; Kawabuchi Y; Ohshita A; Hironaka K
    Hepatogastroenterology; 2008; 55(82-83):407-11. PubMed ID: 18613376
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).
    Ishiguro H; Saji S; Nomura S; Tanaka S; Ueno T; Onoue M; Iwata H; Yamanaka T; Sasaki Y; Toi M
    Cancer Med; 2017 Dec; 6(12):2909-2917. PubMed ID: 29131533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.